Abnormal production of interleukin (IL)-11 and IL-8 in polycythaemia vera.

Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in Polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F

Bone marrow microvessel density and plasma angiogenic factors in myeloproliferative neoplasms: clinicopathological and molecular correlations

Circulating Cytokine Levels as Markers of Inflammation in Philadelphia Negative Myeloproliferative Neoplasms: Diagnostic and Prognostic Interest

Cytokine Regulation of Microenvironmental Cells in Myeloproliferative Neoplasms

Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic Inflammation

An immune dysregulation in MPN.

Transcription factor nuclear factor erythroid-2 mediates expression of the cytokine interleukin 8, a known predictor of inferior outcome in patients with myeloproliferative neoplasms.

nscriptional Profiling of Polycythemia Vera Identifies Gene ression Patterns Both Dependent and Independent

Cancer Therapy: Preclinical Combined Inhibition of Janus Kinase 1/2 for the Treatment of JAK2V617F-Driven Neoplasms: Selective Effects on Mutant Cells and Improvements in Measures of Disease Severity

Combined inhibition of Janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severity.

Abnormal production of interleukin (IL)-11 and IL-8 in polycythaemia vera.

Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in Polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F

Bone marrow microvessel density and plasma angiogenic factors in myeloproliferative neoplasms: clinicopathological and molecular correlations

Circulating Cytokine Levels as Markers of Inflammation in Philadelphia Negative Myeloproliferative Neoplasms: Diagnostic and Prognostic Interest

Cytokine Regulation of Microenvironmental Cells in Myeloproliferative Neoplasms

Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic Inflammation

An immune dysregulation in MPN.

Transcription factor nuclear factor erythroid-2 mediates expression of the cytokine interleukin 8, a known predictor of inferior outcome in patients with myeloproliferative neoplasms.

nscriptional Profiling of Polycythemia Vera Identifies Gene ression Patterns Both Dependent and Independent

Cancer Therapy: Preclinical Combined Inhibition of Janus Kinase 1/2 for the Treatment of JAK2V617F-Driven Neoplasms: Selective Effects on Mutant Cells and Improvements in Measures of Disease Severity

Combined inhibition of Janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severity.

Abnormal production of interleukin (IL)-11 and IL-8 in polycythaemia vera.

Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in Polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F

Bone marrow microvessel density and plasma angiogenic factors in myeloproliferative neoplasms: clinicopathological and molecular correlations

Circulating Cytokine Levels as Markers of Inflammation in Philadelphia Negative Myeloproliferative Neoplasms: Diagnostic and Prognostic Interest

Cytokine Regulation of Microenvironmental Cells in Myeloproliferative Neoplasms

Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic Inflammation

An immune dysregulation in MPN.

Transcription factor nuclear factor erythroid-2 mediates expression of the cytokine interleukin 8, a known predictor of inferior outcome in patients with myeloproliferative neoplasms.

nscriptional Profiling of Polycythemia Vera Identifies Gene ression Patterns Both Dependent and Independent

Cancer Therapy: Preclinical Combined Inhibition of Janus Kinase 1/2 for the Treatment of JAK2V617F-Driven Neoplasms: Selective Effects on Mutant Cells and Improvements in Measures of Disease Severity

Combined inhibition of Janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severity.